Clinical Trials — Cardiovascular

12 supported of 12

2 of 8 pass · 5 warn · 1 fail

Integrity scan

6 findings1 high · 4 medium

stats consistent

3 Adcurare Rigor Reviewers · moderate confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · N Engl J Med0/8Action Items · Critical / High

Multifaceted Strategies for Hypertension Control in Low-Income Patients.

Mills KT, Krousel-Wood M, Peacock EM, Chen J, Allouch F, Carreras AK, Geng S, Cyprian A, Davis G, Fuqua SR, Gilliam D, Greer A, Mitchell T, Gray-Winfrey W, Williams S, Wiltz GM, Winfrey KL, He H, Whelton PK, He J

1.75 / 5

Data and code not sharedConclusions overstated beyond the evidenceInternal contradictions in the reported numbers+1 more

Validated that the CI values: need to correct the 95% confidence intervals for the primary and secondary outcomes in the Results text to include the negative signs (e.g., change '9.0 to 3.8' to '-9.0 to -3.8' and '5.1 to 1.8' to '-5.1 to -1.8'). Agreed on the overstatement.

6 supported · 1 partial · 2 overstated of 9

6 of 8 pass · 1 warn · 1 fail

Integrity scan

3 findings2 medium

3/4 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · BMJ0/12Action Items · Critical / High

Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8)

Attar A, Mirhosseini SA, Mathur A, Dowlut S, Monabati A, Kasaei M, Abtahi F, Kiwan Y, Vosough M, Azarpira N.

2.5 / 5

Key resources not identifiedImplausibly large reported effectInternal contradictions in the reported numbers

10 supported · 2 partial of 12

4/4 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · Nat Med0/8Action Items · Critical / High

Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial.

Sriranjan-Rothwell RS, Zhao TX, Hoole SP, Bond SJ, Tarkin JM, Brubert J, Hubsch A, Helmy J, Bumanlag-Amis E, Jalaludeen N, Templin H, Jiang W, Tedgui A, Zhao X, Nus M, Warnes V, Krishnan U, O'Brien JW, Wall C, Rudd JHF, Cheriyan J, Mallat Z, IVORY investigators

2.75 / 5

Conclusions overstated beyond the evidenceData/code availability incompleteReferences not resolvable to a published paper

6 supported · 1 partial · 2 overstated of 9

7 of 8 pass · 1 warn

4/4 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Observational · Nat Med0/7Action Items · Critical / High

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.

Marston NA, Kany S, Melloni GEM, Jurgens SJ, Kamanu FK, Lai YP, Rämö JT, Raz I, Wiviott SD, Ellinor PT, Sabatine MS, Ruff CT

2.75 / 5

Conclusions overstated beyond the evidenceData/code availability incompleteKey resources under-identified (antibodies, cell lines, RRIDs)+2 more

The greater context of the conclusion is toned down in Abstract: "The findings from this cohort of older and high-risk patients raise the possibility that SGLT2 inhibitor treatment should be started early to prevent HF in individuals who carry P/LP cardiomyopathy variants. These results need to be confirmed in a prospective, dedicated trial of preventive HF treatments in carriers of P/LP cardiomyopathy-associated variants." Confirmed that "Data availability Due to contractual agreements with sponsors, trial data are not available to share."

9 supported · 2 partial · 1 overstated of 12

4/4 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · N Engl J Med0/7Action Items · Critical / High

Endovascular Therapy for Post-Thrombotic Syndrome - A Randomized Trial.

Vedantham S, Kahn SR, Marston WA, Weinberg I, Sista AK, Magnuson EA, Cohen DJ, Wasan SM, Razavi MK, Goldhaber SZ, Sanfilippo KM, Comerota AJ, Azene EM, Chaar CIO, Leung DA, Kolli KP, Kalva SP, Rostambeigi N, Desai A, Desai KR, Tafur AJ, Khalsa B, Majerus E, Wang B, Wang Y, Nieters P, Derfler MC, Oliver A, Hardy C, Bashir R, Winokur R, Weger N, Khaja MS, Sharma A, Mani N, Kavali P, Thukral S, Lake LL, Mikkelsen K, Parpia S, C-TRACT Trial Investigators

3.25 / 5

Data and code not sharedKey resources not identifiedEthics/consent reporting incomplete+1 more

Verified per NEJM that only have data availability as a separate attachment (not accessible to agents using PMC), says: How or where can the data be obtained? NHLBI Data Repository When will data availability begin? One year after completion of the trial Verified odd numbers: “Bleeding (major + non-major) was more frequent in the EVT group (11.6%) than the No-EVT group (3.6%), driven mainly by non-major bleeds (9.8% versus 2.7%). " Also in Table 3 all bleeding had 13, but major bleeding had 4 and non-major bleeding 11 (4+11=15)!

10 supported · 1 partial of 11

5 of 8 pass · 1 warn · 2 fail

Integrity scan

1 finding

1/1 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · Nat Med0/3Action Items · Critical / High

Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial.

Rivard L, Khairy P, Talajic M, Tardif JC, Healey JS, Black SE, Andrade JG, Field TS, Nault I, Bherer L, Massoud F, Nattel S, Lanthier S, Racine N, Roux JF, Greiss I, Macle L, Guerra PG, Tadros R, Mayrand H, Gosselin G, Conen D, Bocti C, Chayer C, Deschaintre Y, Sandhu RK, Manlucu J, Khaykin Y, Verma A, Mondésert B, Dyrda K, Cadrin-Tourigny J, Thibault B, Raymond-Paquin A, Aguilar M, Brouillette J, Roussin A, Robillard A, Tremblay-Gravel M, David LP, Cossette M, Parkash R, Guertin MC, Roy D, BRAIN-AF investigators

3.75 / 5

Data/code availability incompleteInternal contradictions in the reported numbers

11 supported · 1 partial of 12

2/2 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · Nat Med0/7Action Items · Critical / High

The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial.

Solomon SD, McMurray JJV, Felker GM, Januzzi JL, Lam CSP, Voors AA, Claggett B, Nuehrenberg TG, Rizkala AR, Koch C, Zhu W, Lefkowitz MP

3.75 / 5

Statistical reporting gaps (tests, assumptions, effect sizes)Data/code availability incompleteStudy-design details incomplete (controls, blinding, power)+1 more

8 supported · 3 partial of 11

2/2 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · N Engl J Med0/4Action Items · Critical / High

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension

Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B, BaxHTN Investigators.

3.75 / 5

Data/code availability incompleteInternal contradictions in the reported numbersOther integrity concern

8 supported · 4 partial of 12

2/3 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · N Engl J Med0/8Action Items · Critical / High

Home-Based Care for Hypertension in Rural South Africa.

Siedner MJ, Magula N, Mazibuko L, Sithole N, Castle A, Nxumalo S, Manyaapelo T, Abrahams-Gessel S, Gareta D, Orne-Gliemann J, Baisley K, Bachmann M, Gaziano TA

4.25 / 5

Data/code availability incompleteData look implausibly clean

11 supported · 1 partial of 12

1/1 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings

Interventional · BMJ0/3Action Items · Critical / High

Efficacy of dual antiplatelet therapy for three months versus 12 months after coronary artery bypass grafting: multicentre, double blinded, randomised controlled trial.

Yuan X, Li J, Lei L, Zhang L, Chen K, Chu Q, Feng W, Wang X, Wang X, Xu F, Liu S, Yang Y, Wang X, Wang H, Dong A, Cheng Z, Guo H, Zhou T, Chen X, Ge J, Zhang L, Liu S, Shen Z, Wang J, Wang Y, Li W, Hu S, TOP-CABG Collaborative Group

4.75 / 5

Ethics/consent reporting incomplete

10 supported · 2 partial of 12

7 of 8 pass · 1 warn

1/1 links livestats consistentregistered

3 Adcurare Rigor Reviewers · high confidenceAI Rigor Reviewers trained on Adcurare corpus · verify findings